Trial Profile
Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Omeprazole
- Indications Coronary artery disease; Embolism and thrombosis; NSAID-induced gastric damage; Peripheral arterial disorders
- Focus Pharmacodynamics
- 06 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 09 Aug 2010 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 09 Aug 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.